[Reply to @dontaskme - couldn't reply directly for some unknown reason.]
Nothing I have said indicates that I was talking about a 'saliva' trial as distinct from a 'laboratory' trial. What type of trial it was is irrelevant. It FAILED and they did not immediately inform the market. Today's announcement states that the current Indian saliva trial commenced in June, meaning that the UK trial had failed - plenty of time between now and then to make an announcement about the UK trial failure and the decision to revert back to India for a saliva trial.
Instead until now, they just let it be assumed that the UK trial was still proceeding.They have waited to report on UK saliva until they could cushion the blow with this SE Asian distribution deal. Their whole Euro strategy is based on a test 'differentiator' with saliva approval - which now must (at best) be on hold.
Bad, bad look IMO. [Not selling, because the future is still there. I want to know the positive when it occurs and likewise with the negative.]
ADO Price at posting:
23.5¢ Sentiment: Hold Disclosure: Held
